Jci_page_head_homepage_01 Jci_page_head_homepage_02
Michelle Welsh, Philippa T.K. Saunders, Mark Fisken, Hayley M. Scott, Gary R. Hutchison, Lee B. Smith, Richard M. Sharpe
Published in Volume 118, Issue 4
J Clin Invest. 2008; 118(4):1479–1490 doi:10.1172/JCI34241
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
Identification of the early programming window for masculinization of the reproductive tract in rats.

Internal and external genitalia from male rats exposed in utero to flutamide in EW (E15.5–E17.5), MW (E17.5–E19.5), LW (E19.5–E21.5), or FW (E15.5–E21.5) were examined at P25. (A) Schematic diagram of normal masculinization of the indifferent reproductive tissues into their derivative tissues. EW or MW flutamide exposure prevents prostate (B) and seminal vesicle (C) formation in almost all males at P25, while LW flutamide does not prevent prostate or seminal vesicle formation in any males. Ventral prostates (D) and seminal vesicles (E) are significantly smaller in the few EW and MW flutamide-exposed males that had any tissue present. AGD (F) and phallus length (G) are reduced to near female levels in EW and MW flutamide-exposed males at P25. Values are mean ± SEM (n = 8–28 rats from 2–5 litters per treatment group). P > 0.05 compared with female values; ***P < 0.001 compared with control male values. Blue dotted line highlights mean male level; red dotted line highlights mean control female level.